Atnahs Pharma UK Limited - Wyniki wyszukiwania

Australia - angielski - Department of Health (Therapeutic Goods Administration)

kytril granisetron (as hydrochloride) 3mg/ 3ml injection ampoule

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; citric acid monohydrate; sodium chloride; water for injections; sodium hydroxide - adults: kytril (tablets and injection) is indicated for use in adults for: the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric: kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy..

Australia - angielski - Department of Health (Therapeutic Goods Administration)

dipentum olsalazine sodium 500mg tablet bottle

atnahs pharma australia pty ltd - olsalazine sodium, quantity: 500 mg - tablet, uncoated - excipient ingredients: povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; ethanol - indications: treatment of ulcerative colitis in patients intolerant of sulphasalazine.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

toradol ketorolac trometamol 10mg tablet blister pack

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis)

Australia - angielski - Department of Health (Therapeutic Goods Administration)

toradol ketorolac trometamol 30mg/1ml injection ampoule

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory

Australia - angielski - Department of Health (Therapeutic Goods Administration)

toradol 10mg/1ml injection ampoule

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 10 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory